InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.35
(
-0.25%
)
US TECH 100
19,225.40
(
-0.94%
)
Dow Jones
39,122.94
(
0.74%
)
Brent Oil
84.99
(
0.34%
)
Bitcoin
64,952.48
(
-0.04%
)
Post# of 252264
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 110854

Tuesday, 05/17/2011 2:38:00 PM

Tuesday, May 17, 2011 2:38:00 PM

Post# of 252264
AMGN reports additional Xgeva data from phase-3 trial for prevention of bone mets in patients with CRPC:

http://www.reuters.com/article/2011/05/17/amgen-xgeva-idUSN1716488420110517

AMGN reported in Dec 2010 that Xgeva produced a statsig increase in PFS in this indication (#msg-57720261); the new data on secondary endpoints do not change the prospects for Xgeva to a material degree, IMO.

A table of the phase-3 results for Xgeva/Prolia is in #msg-57938233.

“The notion that there’s a Chinese Wall between sell-side analysts
and investment bankers may be the second-biggest piece of BS
ever promulgated in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up